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1. Recognition of peptide and protein phosphorylation 
 
The results presented in this chapter were achieved in collaboration with other scientists. In 
the work on the ditopic receptors, I have synthesized the labeled phosphorylated peptides and 
have performed all binding studies towards peptides 3 and 4. A. Grauer and S. Ritter have 
synthesized the artificial receptors while B. Sperl and T. Berg have performed the STAT1 and 
Chk2 related binding studies. 
In the work on detecting protein phosphorylation on SDS-PAGE, I have performed the 
electrophoresis experiments and established the staining technique. F. Schmidt and S. 
Stadlbauer have synthesized probes 1 and 2. B. König has been supervising both projects. 
 
 
The results of this chapter have been published: 
 
Riechers, A., Grauer, A., Ritter, S., Sperl, B., Berg, T., König, B. Binding of phosphorylated 
peptides and inhibition of their interaction with disease-relevant human proteins by synthetic 
metal-chelate receptors. J. Mol. Recognit. 2009, (in print).  
 
Riechers, A., Schmidt, F., Stadlbauer, S., König, B. Detection of protein phosphorylation on 
SDS-PAGE using probes with a phosphate-sensitive emission response. Bioconj. Chem. 2009, 
20, 804 – 807. 
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1.1 Using ditopic receptors for the recognition of phosphorylated peptides 
 
1.1.1 Introduction 
The selective modulation of protein function by small molecules is still a major challenge in 
medicinal chemistry and molecular biology. Most approaches target the active or allosteric 
binding sites of enzymes or receptors, which are addressed by ligands acting as agonist or 
antagonist. Far less explored is the selective inhibition of protein – protein interactions to 
intercept biological signal transduction. Many of such protein – protein interactions are 
regulated by phosphorylation of one of the binding partners and are of key importance for the 
regulation of essential biological processes, such as cell proliferation. 1, 2 
While an enzyme inhibitor or receptor ligand is accommodated in a well defined binding cleft 
inducing a pharmacologic response, the specific interaction of two proteins typically involves 
much larger surface areas and multiple interactions of complementary functional groups and 
charges. This severely complicates the rational design of inhibitor molecules intercepting 
specific protein interactions making the screening of compound libraries3 or protein crystal 
structure based design analyses4, 5 necessary to identify inhibitors.    
Reversible coordination of metal complexes to charged protein structures provides high 
affinity under physiological conditions and neutralizes protein surface charges upon binding, 
which renders them promising tools for the specific inhibition of protein – protein 
interactions. Although metal chelates have been widely used in molecular recognition,6 only 
few examples of protein function regulation by metal – ligand coordination are known so 
far.7, 8 A particularly suitable target for cationic metal complexes in protein binding are 
phosphorylated amino acid residues due to their negative charges, low abundance and 
importance for the regulation of nearly every cellular process.9, 10, 11 The binding selectivity 
and affinity of metal complex binding sites is enhanced if they are combined with functional 
groups that allow for additional specific interactions with the target peptide sequence. We 
have recently used such ditopic metal complex based receptors for the discrimination of 
phosphorylated peptides with nanomolar affinities.12  
Herein, we report the synthesis of a larger series of metal chelate receptors and their binding 
affinities in a protein inhibition assay. As model protein targets, we chose the human signal 
transducer and activator of transcription protein STAT1 and the serine/threonine kinase Chk2. 
STATs transduce signals from the cell surface to the nucleus13 and contain a Src homology 
 3 
(SH) 2 domain, by which they bind to activated cytokine receptors and growth factor 
receptors. This binding event is prerequisite to the subsequent phosphorylation of STATs at a 
conserved tyrosine residue C-terminal of their SH2 domain, which leads to formation of 
STAT dimers via reciprocal phosphotyrosine-SH2 domain interactions. The so formed STAT 
dimers translocate to the nucleus, where they regulate gene expression.14 Since binding of 
STATs to activated receptors bearing a phosphotyrosine residue is an early step in STAT 
signaling, small molecules like the complexes presented in this work might potentially be 
used as inhibitors of STAT activation. The family member STAT1 mediates responses to 
interferons, and is therefore important for fighting viral and bacterial infections. However, 
because aberrant interferon-mediated signaling leads to inflammatory diseases, STAT1 is also 
a likely target for inflammatory disorders.15 The serine/threonine kinase Chk2 is involved in 
DNA damage signaling and mediates checkpoint activation and cell cycle arrest upon DNA 
damage. It carries a forkhead-associated (FHA) domain, which binds to peptide motifs 
comprising phosphothreonine residues.16  
 
We have previously reported that bis-zinc(II)-cyclen triazine 18 employed as one of the two 
binding sites in the synthetic receptors coordinates to phosphorylated amino acids under 
physiological conditions.12 With lower affinity, this moiety also binds to histidine residues. 
Likewise, we found that a zinc(II)-NTA 19 (nitrilotriacetic acid) complex, which represents a 
truncated EDTA motif can bind carboxylates. The receptors 15 – 17 bear a guanidinium 
moiety as a second binding site since we expected this motif to also bind to carboxylates. 
Histidine and aspartic or glutamic acid, respectively, were thus the secondary binding sites in 
the peptides targeted by our ditopic receptors. We now sought to exploit these binding 
preferences for the design of the potential inhibitors of binding of STAT1 and Chk2, 
respectively, to their phosphorylated peptide recognition motifs. A series of synthetic 
receptors 5 – 17 for peptide binding was prepared, with the receptors differing in their binding 
sites as well as in the length and nature of the linker connecting both binding sites (see Figure 
1). 
The peptide sequence (Flu-GpYDKPHVL, 1) derived from the interferon-γ receptor, which is 
known to play a critical role for STAT1 activation, was chosen for the determination of STAT 
binding inhibition by metal chelates.17 Similarly, the peptide Flu-GHFDpTYLIRR (2) which 
had been described as the optimal ligand of the forkhead-associated (FHA) domain of the 
serine/threonine kinase Chk2,18 was selected as a target for our receptors. To prove the 
respective binding selectivity for imidazole or carboxylate containing amino acid side chains, 
 4 
we also prepared the two peptides Flu-GpSAAEV-NH2 (3) and Flu-GpSAAHV-NH2 (4) 
which do not contain functional side chains beside the two targeted residues. Without other 
functional side chains, they should allow an unambiguous investigation on the influence of 
the secondary binding site. All target peptides are labeled with carboxyfluorescein to allow 
the determination of the binding constants by fluorescence emission and fluorescence 
polarization measurements.  
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Figure 1. Synthetic receptors 5 - 17 and complexes 18 and 19 representing receptor 
substructures. Counterions are omitted for clarity. 
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1.1.2 Results of the binding studies 
 
Binding to peptides 3 and 4 
Fluorescence emission titrations were performed to determine the binding constants of the 
prepared synthetic receptors to peptides 3 and 4. The determined affinities were exemplarily 
verified by fluorescence polarization titrations as an independent method.12 Binding 
stoichiometries were determined by Job’s plot analysis and were found to be 1:1 in all cases.  
As the bis-zinc(II)-cyclen triazine moiety of the receptors 7 – 13 shows a binding affinity for 
phosphorylated amino acids, and the zinc(II)-NTA can bind to carboxylates, we expected a 
marked selectivity for peptide 3 over 4. Table 1 shows that this is indeed the case. 
Furthermore, the significant increase in binding affinity of the ditopic receptors over the 
receptor fragments 18 and 19 indicates additive or even cooperative binding of the individual 
sites to the target peptides.19   
The same binding preference was observed for receptors 14 – 17. In these cases, the 
coordination of the guanidinium moiety to the carboxylate side chain is a likely rational for 
the selectivity. However, differences in binding affinity to peptides 3 and 4 are less 
pronounced with these receptors, probably due to the weaker guanidinium – carboxylate 
interaction if compared to the glutamic acid side chain – zinc(II) –NTA interaction.  
With receptors 5 and 6, the binding affinities are higher for peptide 4 as one bis-zinc(II)-
cyclen triazine can coordinate to the phosphorylated serine while the other binds to the 
imidazole side chain of the histidine. In peptide 3 only the phosphate group is a suitable 
binding partner for receptors 5 and 6 as bis-zinc(II)-cyclen triazine shows no measurable 
affinity to carboxylates.12 
In all cases, we found no marked influence of the length or structure of the linker. This can be 
explained by the fact that peptides as short as the ones used in this study show no defined 
secondary structure in solution. Having determined binding affinities and selectivities to 
model peptides 3 and 4, we selected the synthetic receptors 8, 10, 15, 16 due to their good 
solubility, and the reference compound 18 to investigate their ability to interfere with binding 
between peptides comprising phosphorylated amino acids and their respective protein binding 
partners, STAT1 and Chk2. 
 
 
 
 
 6 
binding affinity [logK] 
receptor 
peptide 4 peptide 3 
5 6.5 5.0 
6 6.5 4.9 
7 5.2 7.5 
8 5.1 8.3 
9 4.8 8.2 
10 5.0 8.4 
11 5.0 7.8 
12 5.4 8.1 
13 5.5 8.1 
14 4.8 7.8 
15 5.2 7.0 
16 4.8 7.7 
17 5.0 6.8 
18 4.8 4.8 
19 < 3 n.d. 
 
Table 1. Binding affinities of receptors 5 – 17 and substructures 18 and 19 to peptides 3 and 
4, reported as logK values ± 0.2. 
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Inhibition of peptide 1 – STAT1 interaction 
The effect of receptors 8, 10, 15, 16, and bis-zinc(II)-cyclen triazine 18 on binding between 
peptide 1 and STAT1 was analyzed by fluorescence polarization (Figure 2). Receptor 18 
served as a reference compound for all measurements. Inhibition by 18 should occur at higher 
concentrations compared to the other receptors as it contains only one binding site. 
 
Figure 2. Effect of receptors 8, 10, 15, 16 and the reference compound 18 on fluorescence 
polarization of peptide 1 in the presence of its natural binding partner STAT1. 
 8 
The measurements revealed that receptor 10 is significantly more potent than reference 
compound 18 at concentrations of 300 µM and higher, and that receptor 8 is also significantly 
more active than 18 at 400 µM and 500 µM. Receptors 15 and 16 are slightly more active 
than 18, but the statistical significance of this effect remains to be investigated.  
 
Inhibition of peptide 2 – Chk2 interaction 
The inhibition of the interaction of peptide 2 with the FHA domain of Chk2 by receptors 8, 
10, 15 and 16 was investigated likewise (see Figure 3). The results show that receptors 8 and 
10 affect the peptide 2 – Chk2 binding at concentrations at 300 µM and higher. The reference 
compound 18 inhibits this peptide – protein binding only at a concentration of 500 µM. 
Again, the ditopic receptors exhibited a higher affinity than the bis-zinc(II)-cyclen triazine 18. 
As with the peptide 1 – STAT1 inhibition, the guanidinium-containing receptors 15 and 16 
show no significantly stronger inhibitory effect than the reference compound 18. 
 
 
Figure 3. Effect of receptors 8, 10, 15, 16 and the reference compound 18 on fluorescence 
polarization of peptide 2 in the presence of its natural binding partner, the Chk2 FHA domain. 
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1.1.3 Discussion of the binding studies 
The fluorescence polarization values monitored in both peptide – protein interaction assays, 
especially in the peptide 2 – Chk2 interaction assay, decrease relatively sharply with 
increasing concentrations of the most active receptors 8 and 10. Furthermore, in case of the 
peptide 2 – Chk2 interaction, fluorescence polarization increases again slightly at higher 
concentrations of receptors 8 and 10. This behavior is consistent with the idea that the 
receptors do not bind to the larger binding partner that is usually targeted in fluorescence 
polarization assays, but instead bind to the fluorophore-labeled peptide. 
 
Binding of the receptors to the fluorophore-labeled peptides increases the fraction of peptides 
that are not bound to the respective target protein and rotate rapidly in solution, and thereby 
decreases fluorescence polarization. However, it can be speculated that this effect can be 
partially masked by two concomitant, opposing effects that instead increase fluorescence 
polarization. Firstly, in the presence of the artificial receptors, the remaining fluorophore-
labeled peptides which are not inactivated by the receptors may bind to their target protein to 
a higher proportion, which would provide a positive contribution to the overall fluorescence 
polarization. This model is supported by the decrease in the dissociation constants (Kd-values) 
of the peptide 2 – Chk2 interaction with decreasing concentrations of peptide 2 (Kd-values of 
the peptide 2 – Chk2 interaction in the presence of 10 nM, 5 nM, 2.5 nM, and 1 nM peptide 2: 
112 ± 7 nM, 90 ± 11 nM, 99 ± 12 nM, and 71 ± 20 nM). Thus, fluorescence polarization 
values of fluorophore-labeled peptide 2 in the presence of Chk2 tend to be higher at lower 
peptide concentrations (Figure 19A). Secondly, binding of the artificial receptors to the 
fluorophore-labeled peptides increases their molecular weight and decreases their rotational 
mobility, again providing a positive contribution to fluorescence polarization. In support of 
this theory, we observed a dose-dependent increase in fluorescence polarization of peptide 2 
in the presence of various concentrations of receptors 8 and 10 (Figure 19B). Both effects can 
be expected to mask low-to-moderate inhibitions obtained at lower concentrations of the 
artificial receptors, and will only be outweighed under conditions of strong disruption of the 
peptide – protein interaction, thus providing a rationale for strong changes of fluorescence 
polarization within a small concentration window of the artificial receptors. The second effect 
furthermore explains why at receptor concentrations exceeding those required for disruption 
of the peptide 2 – Chk2 interaction, a slight dose-dependent increase in the fluorescence 
polarization is observed instead of a further decrease (compare fluorescence polarization 
 10 
values for receptor 10 at 300 µM, 400 µM, and 500 µM; also compare data for receptor 8 at 
400 µM and 500 µM). Consistent with our findings, Hamachi and co-workers had also 
reported a slight increase in fluorescence anisotropy, which is directly linked to fluorescence 
polarization, of a phosphorylated peptide designed to bind to the Pin1 WW domain at high 
concentrations of an effective artificial receptor.20 In addition to that, we have also been 
successful in using fluorescence polarization for detecting the binding of fluorescein-labeled 
peptides and synthetic receptors with similar molecular weight.12 Receptor concentrations 
exceeding 500 µM could not be tested in our assays due to solubility problems at higher 
concentrations. 
 
The most active receptors 8 and 10 affect the peptide 1 – STAT1 interaction somewhat less 
abrupt than the peptide 2 – Chk2 interaction discussed above. It appears conceivable that the 
effects outlined above do no play an equally significant role for this peptide – protein 
interaction. Analysis of the Kd-values of the peptide 1 – STAT1 interaction in the presence of 
10 nM, 5 nM, 2.5 nM, and 1 nM of peptide 1 did not reveal clear trends in affinity (Kd-values 
at 10 nM, 5 nM, 2.5 nM and 1 nM of peptide 1: 141 ± 4 nM, 119 ± 10 nM, 114 ± 8 nM, and 
136 ± 54 nM, respectively), in part caused by the decreased accuracy of the analysis at the 
lowest fluorophore concentration (Figure 20A). Nevertheless, binding of receptors 8 and 10 to 
peptide 1 was evidenced by a dose-dependent increase of fluorescence polarization in the 
absence of STAT1 (Figure 20B). 
 
 
1.1.4 Conclusion 
We have demonstrated the synthesis and use of artificial ditopic metal-chelate receptors for 
the binding of phosphorylated peptides and the inhibition of the interaction between human 
STAT1 and Chk2 proteins and their respective peptide binding sequences. The combination 
of a metal-chelate binding phosphorylated amino acids with a second binding moiety 
increasing the affinity and selectivity should be of general applicability, for example in the 
form of metal-chelate – peptide hybrid receptors. 
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1.1.5 Materials and Methods 
 
Synthesis 
Synthetic details and compound characterization data are provided in the supporting 
information of the publication of this chapter.21  
 
Binding Studies to peptides 3 and 4 
All binding studies were conducted in buffered aqueous solution (50 mM HEPES buffer, pH 
7.5, 154 mM NaCl) with an excitation wavelength of λex = 494 nm at a constant temperature 
of 298 K. A Varian Cary Eclipse fluorometer was used for the emission titrations. The cuvette 
with peptide 3 or 4 in HEPES buffer was titrated stepwise with small amounts (beginning 
with 0.13 eq) of the receptor solution. After each addition the solution was allowed to 
equilibrate for 2 min before the fluorescence intensity and the UV spectrum (where permitted 
by the concentration range) were recorded. The stoichiometries were determined by Job’s 
plots calculated from the titration data. To determine the binding constants, the obtained 
fluorescence intensities at 520 nm were volume corrected, plotted against the concentration of 
receptor and evaluated by nonlinear fitting.  
 12 
Fluorescence-Titrations 
Fluorescence titration results of the receptors 5 – 17 and the receptor substructures 18 and 19 
against the test peptides 3 and 4 are shown below. The blue and red dots represent the 
measured data while the solid black lines represent the non linear fitting of the data. 
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Figure 4. Emission titrations of receptor 5 against peptides 4 (left) and 3 (right). 
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Figure 5. Emission titrations of receptor 6 against peptides 4 (left) and 3 (right). 
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Figure 6. Emission titrations of receptor 7 against peptides 4 (left) and 3 (right). 
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Figure 7. Emission titrations of receptor 8 against peptides 4 (left) and 3 (right). 
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Figure 8. Emission titrations of receptor 9 against peptides 4 (left) and 3 (right). 
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Figure 9. Emission titrations of receptor 10 against peptides 4 (left) and 3 (right). 
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Figure 10. Emission titrations of receptor 11 against peptides 4 (left) and 3 (right). 
 
 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4
concentration 12 [10-5 M]
∆
 
in
te
n
sit
y 
[a.
u
.
]
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
0.0 0.4 0.8 1.2 1.6 2.0
concentration 12 [10-8 M]
∆
 
in
te
n
si
ty
 
[a.
u
.
]
 
Figure 11. Emission titrations of receptor 12 against peptides 4 (left) and 3 (right). 
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Figure 12. Emission titrations of receptor 13 against peptides 4 (left) and 3 (right). 
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Figure 13. Emission titrations of receptor 14 against peptides 4 (left) and 3 (right). 
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Figure 14. Emission titrations of receptor 15 against peptides 4 (left) and 3 (right). 
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Figure 15. Emission titrations of receptor 16 against peptides 4 (left) and 3 (right). 
 
 
0.0
10.0
20.0
30.0
40.0
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6
concentration 17 [10-5 M]
∆
 
in
te
n
si
ty
 
[a.
u
.
]
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6
concentration 17 [10-6 M]
∆
 
in
te
n
si
ty
 
[a.
u
.
]
 
Figure 16. Emission titrations of receptor 17 against peptides 4 (left) and 3 (right). 
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Figure 17. Emission titration of complex 18 representing a receptor substructure against 
peptide 4. 
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Figure 18. Emission titration of complex 19 representing a receptor substructure against 
peptide 4. 
 
Inhibition studies of peptide 1 – STAT1 and peptide 2 – Chk2 interactions 
The test compounds were dissolved in 10 mM Tris pH 7.5. Expression and purification of 
STAT1 and the Chk2 FHA domain have been described.3 Binding assays were performed 
similarly as described.3 In brief, 30 µL of a 16.7 nM solution of either 5-carboxyfluorescein-
GpYDKPHVL (for STAT1) or 5-carboxyfluorescein-GHFDpTYLIRR (for Chk2) were 
incubated with a 5x stock solution of the test compounds (10 µL) for 15 min at room 
temperature. Subsequently, 10 µL of protein (STAT1: 400 nM; Chk2: 600 nM) was added 
and the mixture was allowed to equilibrate for 15 min. The solutions of the fluorescein-
labeled peptides and the proteins were prepared in buffer containing 10 mM HEPES (pH 7.5), 
1 mM EDTA, 0.1% Nonidet P-40, and 50 mM NaCl. Final concentrations: fluorescein-
labeled peptides 10 nM; STAT1 80 nM; Chk2 120 nM. Fluorescence polarization was 
analyzed at room temperature in 384-well plates. All measurements were repeated three times 
in independent experiments. 
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Figure 19. (A) Binding of peptide 2 to the Chk2 FHA domain analyzed by fluorescence 
polarization. The fluorescence polarization of peptide 2 in the absence of protein was 
subtracted from all experimental values. (B) Binding of receptors 8 and 10 to 10 nM of 
peptide 2 analyzed by fluorescence polarization. 
 
 
 
Figure 20. (A) Binding of peptide 1 to the STAT1 SH2 domain analyzed by fluorescence 
polarization. The fluorescence polarization of peptide 1 in the absence of protein was 
subtracted from all experimental values. (B) Binding of receptors 8 and 10 to 10 nM of 
peptide 1 analyzed by fluorescence polarization. 
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1.2 Detection of protein phosphorylation on SDS-PAGE 
 
 
1.2.1 Introduction 
Staining of SDS gels is a standard technique in molecular biology. While silver- and 
Coomassie-staining are widely used for total protein staining, a number of stains selective for 
certain functional groups have emerged. Glycosylation,22, 23 His-tags24 and phosphorylation25, 
26
 are typical protein modifications targeted by selective gel stains reported so far. With 
respect to its biological importance, phosphorylation1, 2 is widely regarded as the most 
significant post-translational modification. Phosphorylation plays an important part in 
signaling pathways and it is estimated that 30 % of the entire proteome becomes 
phosphorylated at some point.27 While there are phospho-specific antibodies available,28, 29 
they require blotting of the proteins onto a polyvinyldifluoride (PVDF) or nitrocellulose 
membrane and may also be specific for additional epitopes in proximity to the 
phosphorylation site. Alternatively, 32P-labeling of the proteins provides a very sensitive tool 
for detection of phosphorylation,30, 31 however, the handling and disposal of radioactive 
material are costly, potentially hazardous and increasingly regulated. When staining for sub-
stoichiometric features such as phosphorylation, fluorescence detection is the method of 
choice due to its inherent sensitivity. The reported32 and commercially available25, 26 
fluorescent phospho-specific stains gain their sensitivity from their binding site specificity. 
While other fluorescent probes for phosphorylated amino acids have been reported,33 their 
selectivity has only been demonstrated for peptides without other metal-chelating amino acids 
like histidine, tryptophan or cysteine. 
Herein, we report two novel phospho-specific gel stains based on the interaction of a metal-
chelate binding site and a covalently attached fluorophore. We have previously described the 
binding of a bis-zinc(II)-cyclen triazine to phosphorylated serine and histidine.12 Since these 
artificial receptors showed high affinity under physiological conditions, we set about using 
this interaction in molecular biology. Based on these findings and a previously reported 
mono-zinc(II)-cyclen coumarin receptor34 which changes its emission wavelength when 
bound to inorganic phosphate in solution, we designed fluorescently labeled bis-zinc(II)-
cyclen triazine complexes for staining of phosphorylated proteins in SDS gels. Bis-zinc(II)-
cyclen triazine was found to have a higher affinity towards phosphate than mononuclear 
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zinc(II)-cyclen complexes and was therefore used as the recognition moiety. As fluorophores, 
we selected the widely employed carboxyfluorescein and 7-(diethylamino) coumarin since a 
similar fluorophore has shown large solvatochromic emission shifts35 which we associate to 
its sensitivity to the environment.36 The resulting probes 1 and 2 are depicted in Figure 1 
while the emission response concept is shown in Scheme 1.  
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Figure 1. Probes 1 and 2 used for staining of phosphoproteins. Counterions are not shown. 
 
 
1.2.2 Results and Discussion of the phosphostaining 
To evaluate the phospho-staining selectivity and sensitivity of our probes, a dilution series of 
phosphorylated bovine α-casein was electrophoretically resolved from the non-phosphory-
lated protein BSA. In addition, a sample of α-casein was dephosphorylated using λ-PPase and 
used as a control to ensure the emission response would not depend on the amino acid 
composition of the protein. After fixation, the gels were stained and destained when necessary 
until little or no background was visible.  
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Scheme 1. Probes 1 and 2 discriminate phosphorylated from nonphosphorylated proteins on 
SDS gels via emission intensity and wavelength shift, respectively. 
 
Probe 1 showed a distinct emission in the bands of phosphorylated α-casein, whereas the 
bands of dephosphorylated α-casein and BSA are barely visible (Figure 2). Bis-zinc(II)-
cyclen triazine complexes coordinate phosphate groups strongly, but we also expect an 
affinity of the probe to non-phosphorylated proteins due to the coordination of histidine by the 
bis-zinc(II)-cyclen triazine12, 37 or further unspecific interactions. However, these interactions 
do not interfere with the specific detection of phosphorylation: The emission of the probe is 
quenched, when bound to non-phosphorylated amino acid residues and the emission remains, 
when bound to phosphorylated amino acid residues. Similar emission quenching effects have 
been previously reported for the interaction of riboflavin with a zinc(II)-imidazole complex38 
and for zinc(II)-porphyrin with histidine.39 To prove that the observed effects originate from 
the coordination of the bis-zinc(II)-cyclen triazine complex and not from the binding of the 
fluorophore itself, a control gel was prepared and treated with carboxyfluorescein. No staining 
could be observed in this experiment.  
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Figure 2. Gel stained with probe 1. Each lane contains 1 µg BSA (66 kDa). From left to right: 
lane 1: 1 µg α-Casein (23 kDa) dephosphorylated, lanes 2 – 8: 1 µg, 500 ng, 250 ng, 125 ng, 
62 ng, 31 ng, 15 ng α-Casein. Top image was taken on a UV table (λex = 316 nm), lower 
image shows CBB R-250 total protein restain.  
 
When bound to phosphorylated α-casein, probe 2 showed a strong redshift in the emission 
compared to unphosphorylated α-casein and BSA (Figure 3). We attribute this spectral 
change to the different electronic environments when the probe molecule is either 
unspecifically interacting with non-phosphorylated amino acid residues, such as histidine 
(unphosphorylated α-casein and BSA) or is coordinating a negatively charged phosphorylated 
amino acid residue (phosphorylated α-casein). These findings are in agreement with the 
reported redshift in emission of a mono-zinc(II)-cyclen coumarin complex upon coordination 
to inorganic phosphate ions.34 To quantify this change in emission, fluorescence spectra of the 
gel bands were obtained using a photonic multi-channel analyzer equipped with a fiber optic 
(Figure 4). As with probe 1, a control gel was treated with the fluorophore itself, and again no 
staining was observed. 
 
With both probes, the dilution series proved that 62 ng of phosphorylated α-casein are still 
detectable on a normal UV-table by the unaided eye (which was protected from UV light) 
while imaging was performed with common digital cameras. Hence, even without the use of 
specialized equipment like laser-illuminated gel scanners or cooled camera detectors as 
described in the protocols of commercially available phosphoprotein gel stains our probes 
reach similar limits of detection.  
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Figure 3. Gel stained with probe 2. Each lane contains 1 µg BSA (66 kDa). From left to right: 
lane 1: 1 µg α-Casein (23 kDa) dephosphorylated, lanes 2 – 8: 1 µg, 500 ng, 250 ng, 125 ng, 
62 ng, 31 ng, 15 ng α-Casein. Top image was taken on a UV table (λex = 316 nm), lower 
image shows CBB R-250 total protein restain.  
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Figure 4. Normalized emission spectra of gel bands stained with probe 2 acquired through a 
455 nm longpass filter (λex = 316 nm). BSA band showed the same spectrum as 
dephosphorylated α-casein (data not shown).  
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1.2.3 Conclusion  
We have demonstrated the application of two new non-covalent, reversible and fluorescent 
SDS-PAGE probes capable of indicating protein phosphorylation. The probes show different 
fluorescence responses discriminating phosphorylated from non-phosphorylated proteins. 
While probe 1 signals binding to a phosphorylated protein by a significant increase of 
emission intensity, probe 2 is the first phosphoprotein gel stain to change its emission 
spectrum upon binding to a phosphorylated protein. The probes achieve their selectivity 
through a combination of the specificity of the dinuclear metal chelate binding site towards 
phosphate oxoanions and a modulation of the chromophore emission due to the proximity of 
the phosphorylated amino acid. The environment-sensitive fluorophores allow a clear 
distinction between phosphorylated and non-phosphorylated proteins on SDS-PAGE and 
allow the detection of 62 ng of phosphorylated α-casein on a normal UV-table. Evaluations of 
other metal chelate fluorophore conjugates and applications of the existing probes to monitor 
signaling pathways are currently under way.  
 
 
 
 
1.2.4 Materials and Methods 
 
Synthesis 
Detailed information on the synthetic procedures and compound characterization data are 
provided in the supporting information of the publication of this chapter.40  
 
Dephosphorylation by λ-PPase treatment 
Bovine α-casein (40 µg, purchased from Sigma-Aldrich) was treated with 400 U of λ-PPase 
(purchased from New England Biolabs) in Tris-HCl (50 mM), NaCl (100 mM), dithiothreitol 
(2 mM), MnCl2 (2 mM), EGTA (0.1 mM), 0.01 % Brij 35, pH 7.5 at 30 °C for 6 h.  
 
SDS-PAGE 
Proteins were resolved on mini gels under denaturating and reducing Laemmli conditions on a 
PeqLab 45-1010-i apparatus. The gels consisted of a 4 % acrylamide (w/v), 120 mM Tris-HCl 
(pH 6.8), 0.1 % SDS (w/v) stacking gel and a 15 % acrylamide (w/v), 375 mM Tris-HCl (pH 
8.8), 0.1 % SDS (w/v) running gel. A 25 mM Tris, 192 mM glycine, 0.1 % SDS (w/v) 
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running buffer (pH 8.3) was used. Protein samples were heated to 70 °C for 10 min with 
reducing and denaturating RotiLoad 1 sample buffer (purchased from Carl Roth, Germany) 
before being loaded onto the gel. The gels were run at 150 V until the proteins entered the 
running gel, then the voltage was increased to 250 V. Water cooling was used during the 
entire run. Fixation was accomplished by treating the gels with 50 % MeOH, 10 % AcOH 
twice, for 30 min and overnight, respectively.  
 
Staining and Imaging 
The gels were soaked in deionized water (4 x 10 min) before being treated with a solution of 
probe 1 or 2 in deionized water for 1 h with a probe concentration of 10-7 M. We found 
destaining was not strictly necessary at this concentration, however, when the probes were 
used at higher concentrations, the gels could be destained by washing with deionized water 
until a nonfluorescent background was obtained. Due to their non-covalent binding mode,6 the 
probes could be completely removed by repeated washing of the gel with water. 
Conveniently, removal of the probes was not necessary for Coomassie restaining. 
The gels were wrapped in cling film to prevent them from drying out and placed on a PeqLab 
Superbright UV table (λex = 316 nm). Images were taken using either a Pentax K10D or a 
Traveler DC 8500. Emission spectra of individual protein bands were obtained using the same 
UV table and a Hamamatsu PMA-11 photonic multi-channel analyzer. Data were acquired 
using the supplied PMA Optic software. A 455 nm longpass filter was placed on top of the gel 
to prevent the UV light saturating the detector. Longpass filters with a shorter cutoff proved 
unsuitable as they showed a strong fluorescence when subjected to the UV light.  
After fluorescence imaging, a restain for total protein was accomplished with 0.1 % 
Coomassie R-250, 50 % MeOH, 10 % AcOH for 1 h. Destaining was accomplished in 7 % 
AcOH, 10 % MeOH over night. The gels were again wrapped in cling film and scanned using 
an office scanner.  
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2. Inhibition of melanoma inhibitory activity (MIA) 
protein 
 
 
The results presented in this chapter were achieved in collaboration with other scientists. I 
have focused on peptide synthesis, establishing the HTFP assay and screening the peptide 
libraries as well as performing other in vitro analyses such as Western blotting. J. Schmidt has 
performed most of the cell culture experiments, including all immunofluorescence studies and 
cloning. R. Stoll has conducted the NMR experiments, while C. Hellerbrand and T. Amann 
have helped conducting the animal experiments. W. Gronwald and F. Fink have performed 
the in silico studies. B. König and A. K. Bosserhoff have been supervising this project. 
 
 
The results of this chapter have been either published or submitted for publication: 
 
Riechers, A., Schmidt, J., König, B., Bosserhoff, A. K. Heterogeneous Transition Metal-based 
Fluorescence Polarization (HTFP) Assay for Probing Protein Interactions. Biotechniques 
2009, 47, 837 – 844. 
 
Schmidt, J., Riechers, A., Stoll, R., Amann, T., Fink, F., Hellerbrand, C., Gronwald, W., 
König, B., Bosserhoff, A. K. Dissociation of functionally active MIA protein dimers by 
dodecapeptide AR71 strongly reduces formation of metastases in malignant melanoma. Nat. 
Med. 2010, (submitted). 
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2.1 Development of a screening assay for inhibitors of melanoma inhibitory 
activity (MIA) protein 
 
 
2.1.1 Introduction 
Protein interactions play a fundamental role in many biochemical processes like signal 
transduction, immune reaction, cell cycle control, differentiation and protein folding. The 
search for potent and selective inhibitors for specific protein-protein binding events is 
essential in pharmaceutical drug design and various techniques have been established for 
probing protein interactions. One commonly used screening method is an in-solution 
fluorescence polarization (FP) assay; in this technique, the rotational mobility of a 
fluorescently labeled entity is assessed in order to provide information about whether it is in a 
bound or unbound state. Clearly, this method is dependent upon a significant difference in 
molecular weight between the unbound fluorescently labeled entity versus when it is part of a 
binding complex. Here, we describe a high-throughput FP-based screening assay that is 
compatible with both high and low molecular weight interaction partners.  
We have termed our method the heterogeneous transition metal-based fluorescence 
polarization (HTFP) assay. Compared to organic fluorophores, luminescent transition metal 
complexes have a number of advantages, such as a large Stokes shift, high photostability and 
the option to be used in time-gated measurements. These time-gated measurements offer the 
possibility of multiple labeling using transition metals with different lifetimes despite possible 
spectral overlap and the elimination of autofluorescence of biological material. Although 
luminescent transition metal complexes have been used in FP immunoassays,41, 42, 43, 44, 45, 46, 
47, 48, 49, 50, 51, 52, 53
 these reagents are not feasible for use in binding investigations of low 
molecular weight compounds in solution, for example in drug candidate screening, due to the 
dependence of fluorescence polarization on molecular weight and fluorescence lifetime. 
Therefore, instead of performing the assay in free solution, we have anchored one of the 
binding factors to the surface of a well in a multiwell plate. This surface-bound factor is then 
incubated with its fluorescently labeled protein partner and other compounds being tested for 
binding activity. In the absence of a competitive inhibitor, the protein is tethered to the well’s 
surface and has limited ability to rotate. However, in the presence of a compound that can 
compete away the binding between the protein and its immobilized binding partner, the 
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protein is freed into solution, and the resulting increase in its rotational diffusion can be easily 
detected by FP measurements.    
We demonstrate the HTFP assay in a screen of melanoma inhibitory activity (MIA) protein 
inhibitors. MIA protein, an 11 kDa molecule produced under physiological conditions by 
cartilage, is strongly expressed and secreted by malignant melanoma cells, but is not 
expressed in melanocytes.54, 55 Since MIA protein expression level in vivo directly correlates 
with progressive malignancy of melanocytic tumors, it serves as a reliable clinical tumor 
marker to detect and monitor metastatic diseases.56, 57 Recent data describe a direct interaction 
of MIA protein with the cell adhesion receptors integrin α4β1 and integrin α5β1 and with 
extracellular matrix molecules, including fibronectin.58, 59 By modulating integrin activity and 
masking matrix structures, MIA protein mediates detachment of melanoma cells, resulting in 
enhanced invasive and migratory potential that ultimately contributes significantly to the 
formation of metastasis.60 To prevent metastasis, it is desirable to find substances that 
specifically bind to MIA protein and thereby reduce MIA-induced effects. Here, MIA and 
known binding partners were used to develop the HTFP assay as a high-throughput method to 
identify and characterize protein interactions. 
 
2.1.2 Results of the HTFP assay studies 
In previous studies, FN14, a peptide that matches a fibronectin domain, was identified as an 
MIA binder in a phage display experiment.61 AR54, an MIA-binding peptide deduced from 
peptide FN14, has been shown by Boyden Chamber invasion assay to functionally inhibit 
MIA protein in vitro. The peptide was able to almost completely inhibit MIA protein function 
by preventing interactions of MIA protein with extracellular matrix molecules and integrins 
without affecting cell migration itself.62 Using AR54 as a known inhibitor of MIA protein, we 
aimed to establish an assay which allows detection of potential MIA-inhibitory compounds. 
Commonly used methods for investigating protein interactions, like fluorescence emission 
titration (a method that is generally used to obtain information about stoichiometry and 
binding constants) and fluorescence resonance energy transfer (FRET)-based experiments, 
were found to be inappropriate. This failure was due to inherent tendency of MIA protein to 
form aggregates;61 moreover, a FRET experiment with an N-methylanthraniloyl labelled 
AR54 derivative failed due to spectral overlap. Since dynamic light scattering (DLS), nuclear 
magnetic resonance (NMR), and isothermal titration calorimetry (ITC) were not sensitive 
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enough to detect binding events at physiologically relevant concentrations, we decided to 
employ FP for elucidating the interaction of MIA protein with AR54.  
FP experiments with a carboxyfluorescein-labeled derivative were compromised by 
nonspecific interactions of both MIA protein and the respective control protein with the 
fluorophore. We therefore reevaluated the choice of our assay format and decided to establish 
a new FP-based assay in which the protein rather than the inhibitor was labeled. In this 
scenario, we envisioned that the change in molecular weight resulting from binding would be 
observable only if the labeled protein of interest (MIA) was bound by an inhibitory compound 
(AR54) immobilized to a well plate (Figure 1). The FP signal should decrease after 
competitive displacement of labeled MIA protein from immobilized AR54 by an inhibitory 
compound.  
 
Figure 1. Concept of the FP assay using a luminescent transition metal complex as the label.  
Binding of Ru(bpy)3-labeled MIA protein to the immobilized inhibitory peptide AR54 leads 
to a large change in molecular weight, resulting in a dramatic increase of the fluorescence 
polarization signal (left). After competitive displacement of labeled MIA protein from 
immobilized AR54 by an inhibitory compound (right) the FP signal decreases. The HTFP 
assay should enable high-throughput screening of large substance libraries for potent MIA 
protein inhibitors. 
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As a label, we chose the luminescent Ru(bpy)3 (tris(2,2'-bipyridine)ruthenium (II)) complex 
due to its sufficiently long lifetime. To ensure that Ru(bpy)3 does not affect binding properties 
of MIA protein, we performed Boyden Chamber invasion experiments, where Mel Im cells 
were treated with Ru(bpy)3-labeled MIA protein and, in comparison, with unlabeled MIA 
protein. Non-modified MIA protein reduces cell invasion by about 40 % to 50 % in this in 
vitro model because MIA protein specifically interferes with attachment of melanoma cells to 
matrigel.60 We found that unlabeled and labeled MIA protein behave identically, confirming 
that Ru(bpy)3-labeled MIA is functionally active (data not shown).  
 
Binding of MIA-Ru(bpy)3 to AR54, 30 kDa and 70 kDa fibronectin fragments 
First, we measured the FP signal of MIA-Ru(bpy)3 in a well coated with AR54-biotin 
compared to an uncoated well. The significant increase in FP in the well coated with AR54-
biotin was attributed to the severely restricted rotational mobility of MIA-Ru(bpy)3 bound to 
the immobilized AR54-biotin (Figure 2). In order to assess whether we could displace MIA-
Ru(bpy)3 from the immobilized AR54-biotin, we treated this complex with 7.8 µM AR54 in 
solution. In this case, the FP of MIA-Ru(bpy)3 was almost identical to MIA-Ru(bpy)3 free in 
solution (in a well not coated with AR54-biotin). This demonstrates that the molecular 
mobility is unhindered and that the binding is reversible.  
 
 
 
 
 
 
 
 
 
Figure 2. HTFP assay investigation of interaction of AR54 with MIA-Ru(bpy)3. In the AR54-
biotin treated well, the FP signal increases due to binding of Ru(bpy)3-labeled MIA protein to 
immobilized AR54 peptide. After addition of AR54 at a final concentration of 7.8 µM, the 
detected FP of MIA-Ru(bpy)3 is almost identical to the MIA-Ru(bpy)3 free in solution (in a 
well not coated with AR54-biotin), demonstrating that after displacement from immobilized 
AR54-biotin, the molecular mobility is unhindered. 
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The interaction of MIA with fibronectin has been described previously.59 In order to test our 
assay with this known interaction partner, we applied 30 kDa and 70 kDa proteolytic 
fragments of human fibronectin, as shown in Figure 3A. As expected, FP decreased upon 
addition of the fibronectin fragments. Taken together with the AR54 results, this finding 
demonstrates that our HTFP assay is capable of detecting protein interactions with a small 
peptide as well as a 70 kDa protein. 
Next, we performed a titration of MIA-Ru(bpy)3 with the 30 kDa fibronectin fragment to 
demonstrate that our assay is also capable of determining binding constants. As presented in 
Figure 3B, we determined a Kd value of 33 nM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. HTFP assay investigation of interaction of 30 kDa and 70 kDa fibronectin 
fragments with MIA-Ru-(bpy)3. (A) 30 kDa and 70 kDa proteolytic fragments of human 
fibronectin, known to interact with MIA protein, were applied in the HTFP assay. The FP 
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signal decreases, indicating a displacement of MIA protein from AR54-Biotin. (B) Titration 
of MIA-Ru(bpy)3 with 30 kDa human proteolytic fibronectin fragment. The observed Kd is 33 
nM. All experiments were performed in triplicate. 
 
 
 
Buffer additives and detergent controls 
To assess the suitability of the HTFP assay as a screening platform for the identification of 
potential MIA protein inhibitors, we investigated the influence of various buffer additives and 
detergents commonly used in molecular biology. As expected, the addition of 0.1 % Triton X-
100 or 0.1 % 2-mercaptoethanol disrupted the interaction of MIA-Ru(bpy)3 and AR54-biotin 
(data not shown). DMSO, which is often used in inhibitor screenings for dissolving 
compound libraries, could be tolerated for concentrations of up to 2.5 %, but the addition of 
50 mM EDTA (ethylenediamine tetraacetic acid) induced a significant decrease in FP signal 
(data not shown). This can be explained by a photoinduced redox reaction involving the 
luminescent label Ru(bpy)3 and EDTA.63 Consistent with this proposed mechanism, a similar 
decrease was also observed in the absence of AR54-biotin. 
 
Multimerization studies 
Although aggregation can lead to artifacts in other binding experiments, we hypothesized that 
our assay, with its long lifetime of the luminescent label, should be beneficial for 
investigating proteins prone to multimerization. The addition of an excess of unlabeled MIA 
protein to MIA-Ru(bpy)3 does not change FP (Figure 4A), indicating that the size of the 
multimers does not change and that there are no aggregates consisting of about ten or more 
molecules. We estimate this from the lifetime of the label and the molecular weight of the 
protein by the Perrin equation. To demonstrate the existence of smaller aggregates, we coated 
wells with a MIA-biotin conjugate. Indeed, a large increase in FP was detected, indicating the 
presence of direct MIA-MIA interactions. The formation of multimeric structures of MIA 
protein was also confirmed by Western blot analysis as shown in Figure 4B. These aggregates 
appear to be extraordinarily stable since they can even be observed after treatment with 
denaturing and reducing Laemmli buffer at 70 °C.   
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Figure 4. HTFP assay investigation of MIA protein aggregation. (A) Analysis of MIA 
aggregation was performed under physiological conditions using DPBS buffer in an AR54-
uncoated well. (B) As also demonstrated by Western blot analysis, 11 kDa MIA protein forms 
multimeric structures. All experiments were performed in triplicate. 
 
 
2.1.3 Discussion of the HTFP assay studies 
Several methods have been developed for the investigation of protein interactions. While 
surface plasmon resonance (SPR) 64 can also be used for small-molecule interactions with the 
help of antibodies, it is still costly because proprietary chips are generally required. Far-
Western blotting is time consuming and also not suitable for high-throughput applications.65 
Furthermore, this method relies on the refolding of the protein to its native conformation on 
the membrane, which may not always be successful. Immunoprecipitation and pull-down 
experiments are also far more time-consuming than fluorescence-based investigations.66 
Binding experiments using the 1-anilino-8-naphthalene sulfonate (ANS) probe,67 while 
compatible with multiwell plate-based assays, suffer from short excitation and emission 
wavelengths. Automated isothermal calorimetry measurements offer the advantage of label-
free detection, but still require relatively large amounts of substance. 
Methods capable of handling high-throughput screening include various types of microarrays 
using enzymes, isotopes, or fluorescent labels. However, these techniques require special 
safety precautions, antibodies, and washing steps that may lead to cross-contamination and 
other artifacts.  
FP detection is both high-throughput capable and self-referenced, meaning that no washing 
steps are required. This is clearly an advantage over the traditional ELISA (enzyme-linked 
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immunosorbent assay) platform. Traditional homogeneous FP assays are limited by the 
molecular weight of the interaction partner to be investigated, due to the short lifetime of the 
required organic fluorophores. We extend this range by immobilizing a known interaction 
partner of the protein of interest, which is itself labeled with a long-lifetime luminescent 
transition metal chelate. The maximum acceptable molecular weight of the interaction partner 
obviously depends on the decay time of the label on the target. Given the decay time of 
Ru(bpy)3, we estimate from the Perrin equation 68 that interactions with binding partners of up 
to 500 kDa should still be observable, however, that limit could be raised by using a transition 
metal with a longer decay time.  
The results show that our HTFP assay allows the investigation of protein-small molecule as 
well as protein-protein interactions. Thus, in contrast to traditional homogeneous FP assays, 
interactions with both high and low molecular weight compounds can be investigated. As 
presented for the interaction of MIA protein with AR54, this FP assay should also be 
amenable for the screening of libraries of potential drug candidates. Additionally, our HTFP 
assay is suitable for the investigation of protein aggregation and compounds cleaving these 
aggregates. This tolerance of the HTFP assay for aggregation makes it unique and should 
allow the investigation of proteins which show aggregation-related artifacts in other assays. 
However, one limitation of our assay is the fact that it will be difficult to estimate aggregate 
sizes from the polarization values due to the long decay time. 
Since our assay format is applicable to a variety of situations, it is conceivable that it also 
might be used for other analytical or diagnostic applications. For instance, the HTFP assay 
would be expected to enable the investigation of protein complexes, such as cell signaling 
molecules, transport proteins, or transcription factors. It could also be used for the 
identification of an initiator or regulator of polymerization reactions, for instance for actin or 
tubulin subunits within the dynamic processes of the cytoskeleton. This assay may also serve 
to identify activators or co-activators for enzymatic reactions as well as for the design of 
immunoassays in the field of serology and diagnostics. Since the HTFP assay is based on a 
luminescent transition metal complex label, it benefits from all the associated advantages over 
organic fluorophores. While the inherent photostability is obviously convenient, the large 
Stokes shift increases the signal-to-noise ratio and allows a broader selection of suitable 
emission filters for the spectrometer. Furthermore, the long lifetime of transition metal 
complex labels also opens the possibility of time-gated measurements. This may be employed 
for multi-label experiments with different transition metal complexes of different lifetimes, 
allowing these labels to be resolved regardless of spectral overlap. Finally, complex biological 
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matrices in the samples are also tolerable because the autofluorescence of biological material 
has a very short lifetime and can thus be eliminated.  
 
 
2.1.4 Materials and Methods 
 
Cell lines and cell culture conditions 
The melanoma cell line Mel Im, established from a human metastatic tumor sample (a 
generous gift from Dr. Johnson, University of Munich, Germany), was used in Boyden 
Chamber invasion experiments. Cells were maintained in DMEM (Dulbecco’s Modified 
Eagle Medium; PAA Laboratories GmbH, Austria) supplemented with penicillin (400 U/mL), 
streptomycin (50 µg/mL), l-glutamine (300 µg/mL) and 10 % fetal calf serum (Pan Biotech 
GmbH, Germany) and split in a 1:5 ratio every three days. 
 
Boyden Chamber Invasion Assay 
Invasion assays were performed in Boyden Chambers containing polycarbonate filters with 8 
µm pore size (Neuro Probe, Gaithersburg, MD, USA) essentially as described previously.69 
Filters were coated with Matrigel, a commercially available reconstituted basement membrane 
(diluted 1:3 in H2O; BD Bioscience, Bradford, MA, USA). The lower compartment was filled 
with fibroblast-conditioned medium used as a chemoattractant. Mel Im melanoma cells were 
harvested by trypsinization for 2 min, resuspended in DMEM without fetal calf serum (FCS) 
at a density 2.5 x 104 cells/mL, and placed in the upper compartment of the chamber. Except 
for the control experiment with untreated cells and experiments where cells were only treated 
with the peptide, MIA protein or Ru(bpy)3-labeled MIA protein, respectively, was added to 
the cell suspension at a final concentration of 200 ng/mL. Peptide AR54 (sequence: 
NSLLVSFQPPRAR) was used at a final concentration of 1 µM. After incubation at 37° C for 
4 h filters were removed. Cells adhering to the lower surface of the filter were fixed, stained, 
and counted. Experiments were carried out in triplicates and repeated at least three times. 
 
Protein analysis by Western blotting 
MIA protein was denaturated at 70°C for 10 min after addition of reducing and denaturing 
Roti-Load buffer (Roth, Karlsruhe, Germany) and subsequently separated on sodium dodecyl 
sulfate 12.75 % polyacrylamide gels (SDS-PAGE) (Invitrogen, Groningen, The Netherlands). 
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After transferring the proteins onto a polyvinylidene fluoride (PVDF) membrane (BioRad, 
Richmond, VA, USA), the membrane was blocked using 3 % bovine serum albumin (BSA) in 
phosphate-buffered saline (PBS) for 1 h at room temperature (RT) and incubated with a 1:150 
dilution of primary polyclonal rabbit anti-MIA antibody  (Biogenes, Berlin, Germany) in 3 % 
BSA/PBS overnight at 4°C. After washing in PBS the membrane was incubated with a 1:2000 
dilution of an alkaline-phosphatase coupled secondary antibody (Chemikon, Hofheim, 
Germany) for 2 h at RT. Finally, after washing steps, immunoreactions were visualized by 
nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) (Invitrogen) 
staining.  
 
Luminescent labeling of human MIA protein 
Human MIA protein (100 µg) was labeled with Ru(bpy)3-isothiocyanate (1 mg) (Active Motif 
Chromeon, Germany, cat# 15412) in 640 µL bicarbonate buffer pH 9.3 supplemented with 
200 µL DMSO (dimethylsulfoxide) required for dissolving the dye. After 50 min, the reaction 
mixture was purified on a size-exclusion column (SephadexTM G-25 M PD-10 Desalting 
column, Amersham Pharmacia Biotech, Sweden) and samples of the collected fractions as 
well as a dilution series of unlabeled MIA protein were analyzed by Western blotting as 
described above.  
 
Biotin conjugation of peptide AR54 
0.25 mg of AR54 was dissolved in 30 µL of bicarbonate buffer pH 9.3. After addition of 0.38 
mg biotin-NHS ester (Calbiochem, USA, cat# 203188) in 10 µL DMSO the reaction mixture 
was incubated overnight at 4 °C. As the NHS-ester was expected to be completely reacted or 
hydrolyzed, no purification was carried out.  
 
Coating of well plates with AR54-biotin and MIA-biotin 
Black streptavidin-coated 96 well plates (Greiner Bio-one, Germany, cat# 655997) with a 
loading of 20 pmol streptavidin per well were treated with 20 equivalents AR54-biotin per 
mol of (tetrameric) streptavidin in PBS pH 7.4. An uncoated control lane was sealed with 
adhesive film to prevent contamination with AR54-biotin. After addition of AR54-biotin, the 
entire plate was sealed with adhesive film and incubated for 3 h under agitation. The coated 
lanes were washed five times with PBS pH 7.4 before being air-dried and sealed with 
adhesive film which was removed only immediately before use of each lane.  
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MIA-biotin was prepared as previously reported59 and used for treating a well plate as 
described above, except that the plate was not dried and used for measurements immediately. 
 
Polarization assay setup 
All measurements were performed at room temperature on a Polarstar Optima microplate 
reader (BMG Labtech, Germany). A 390-10 nm bandpass filter was used for excitation while 
a 520 nm longpass filter was used for the emission light. Even though the extinction 
coefficient is higher at longer wavelengths, we chose a shorter excitation wavelength as this 
led to higher polarization values. A MIA-Ru(bpy)3 concentration of 55 fM was used in all 
experiments. A solution volume of 250 µL per well was found to give a low standard 
deviation with high signal intensity. Unless otherwise indicated, all measurements were 
performed in DPBS without calcium or magnesium (PAN Biotech GmbH, Germany). 
Addition of components to the wells was done in the following order: Interaction partner, 
buffer, MIA-Ru(bpy)3. Owing to different reaction kinetics, measurements were performed 
every 5 min over a 30 min period. Polarization values are reported relative (P/P0) to the value 
of free MIA-Ru(bpy)3 in solution in a well not treated with AR54-Biotin. All reported values 
are an average of three independent measurements. 
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2.2 Dissociation of functionally active MIA dimers by dodecapeptide AR71 
strongly reduces formation of metastases in malignant melanoma  
 
 
2.2.1 Introduction 
Malignant melanoma is characterized by aggressive local growth and early formation of 
metastases. In order to identify autocrine growth-regulatory factors secreted by melanoma 
cells, melanoma inhibitory activity (MIA), an 11 kDa protein, strongly expressed and secreted 
by melanocytic tumor cells was purified from tissue culture supernatant of the human 
melanoma cell line HTZ-19.54, 70 Today it serves as a reliable clinical serum tumor marker for 
detection of metastatic diseases and monitoring therapy responses of patients suffering from 
malignant melanoma. In addition, MIA plays an important functional role in melanoma 
development and cell invasion as its expression levels directly correlate with the capability of 
melanoma cells to form metastases in syngeneic animals.60, 71, 72  
After transcription, MIA mRNA is translated into a 131 amino acid precursor molecule and 
processed into a mature protein consisting of 107 amino acids after cleavage of the secretion 
signal sequence.70 The transport of MIA protein to the cell rear is induced after migratory 
stimuli.73 Following secretion, MIA subsequently binds to cell adhesion receptors integrin 
α4β1 and integrin α5β1. In addition, MIA masks their binding sites at ECM molecules 
including fibronectin, laminin and tenascin.59, 60 Consequently, cell adhesion contacts are 
reduced, enabling tumor cells to migrate and invade into healthy tissue, resulting in enhanced 
metastatic potential.  
Previously, the three-dimensional structure of MIA protein was solved by multidimensional 
nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography techniques.74, 75, 
61, 76, 77
 Corresponding data indicated that MIA defines a novel type of secreted protein 
comprising an SH3 domain like fold.  
In the present study we aimed to determine the so far unknown molecular mechanism of MIA. 
By functionally analyzing MIA mutants we demonstrate for the first time that MIA achieves 
functional activity by self assembly. Peptidic dimerization inhibitors were identified and 
analyzed in in vitro and in vivo studies, thus providing an excellent starting point for the 
development of a new inhibitory strategy. Based on these new data presented here, the 
rational design and development of a novel pharmacophore which inhibits MIA and thus 
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strongly reduces tumor cell invasion and formation of metastases could provide a key element 
in malignant melanoma therapy. 
 
2.2.2 Results of the inhibition studies 
 
MIA protein is functionally active as a dimer 
Although MIA was thought to act as a monomer, recent data suggests that, as detailed below, 
the active form of the protein consists of a dimer. Using the PreBI modelling software 
(http://pre-s.protein.osaka-u.ac.jp/prebi/) for the prediction of the putative dimer interface 
together with the HADDOCK protein-protein docking program,78 we obtained a model of the 
MIA dimer comprising a head to tail linkage (Figure 1A). The dimerization interfaces are 
located around Y30 and at the region K53-L58 in the n-Src loop and the cleft next to Q65-
A73 in the distal loop. Further supporting our results, the regions determined to form the 
interface have been described as crucial for functional activity in a previous mutagenesis 
study.69 In addition, Western blot analysis of MIA also demonstrates that apart from the 
monomeric species dimers exist.79 We, therefore, aimed to investigate the physiological 
relevance of MIA dimers and the possible correlation between dimerization and functional 
activity. Having identified the most likely positions of the dimerization interfaces, mutants of 
MIA were tested for their capability to form dimers by Western blot analysis (Figure 1B). 
MIA mutants were expressed in an in vitro transcription/translation system. All mutants 
showed correct folding as evidenced by an MIA-ELISA and were selected as not carrying a 
mutation in the dimerization regions, apart from G61R.69 Recombinant wt MIA and all 
mutants clearly show a dimer band except for G61R. Interestingly, all mutants but G61R are 
functionally active in Boyden chamber invasion assays, as presented in Figure 1C. MIA wt 
(RTS) and mutants D29G/Y69H, V46F/S81P, T89P and K91N can exhibit this effect to the 
same extent while MIA mutant G61R completely loses activity. The sites of mutations not 
affecting functional activity (Figure 1D, depicted in grey) are located outside the dimerization 
regions, whereas G61R (Figure 1D, depicted in magenta) is buried in the dimerization cleft 
(depicted in red) in close proximity to the distal loop.  
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Figure 1. MIA protein is functionally inactive as a monomer. (A)  Structure of the MIA dimer 
according to shape complementarity analyses. The MIA dimer is characterized by a head-to-
tail orientation, with the dimerization domains consisting of the n-Src loop and the cleft next 
to the distal loop. (B) Western blot analysis of MIA mutants assessing their ability to form 
dimers. The first lane shows recombinant wt MIA, followed by the same protein in an 
unpurified RTS expression system (wt) and mutants D29G/Y69H, V46F/S81P, T89P, K91N 
and G61R. All homologues, except for G61R, clearly show a dimer band. (C) Correlation 
between dimerization and functional activity revealed that all MIA mutants capable to 
dimerize are functionally active in Boyden chamber invasion assays as reflected by a 
reduction in the number of invaded cells due to interference with cell adhesion. Mutant G61R, 
which does not form protein dimers does not show any MIA induced effect. (D) NMR 
structure of MIA showing the dimerization domains and the mutation sites. The dimerization 
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domains in the n-Src loop and next to the distal loop are depicted in blue and red, 
respectively. Mutation sites which do not influence dimerization and functional activity are 
shown in grey and obviously lie outside the dimerization domains. The site of mutation 
G61R, which is in direct contact with the dimerization domain next to the distal loop, is 
shown in magenta. This figure was generated using PyMol (Delano, W. L., The PyMol 
Molecular Graphics System (2002) Delano Scientific, Palo Alto, CA, USA). 
 
Peptide AR71 prevents MIA protein dimerization  
We then aimed to identify peptides inhibiting MIA dimerization in a newly developed 
heterogeneous transition-metal based fluorescence polarization (HTFP) assay.79 First, MIA-
MIA interaction was confirmed using this assay. Here, we immobilized a MIA-biotin 
conjugate in a streptavidin-coated well plate and added MIA labelled with the luminescent 
transition-metal complex Ru(bpy)3. As depicted in Figure 2A, a significant increase in FP 
signal in the wells coated with MIA-biotin was observed compared to control wells not 
functionalized with MIA-biotin. This was attributed to the severely restricted rotational 
mobility of MIA-Ru(bpy)3 bound to the immobilized MIA-biotin.   
We then screened peptides, previously identified by phage display and known to generally 
bind to MIA,61 for their potential to prevent MIA dimerization and induce dissociation of 
already existing protein dimers using the HTFP assay. As shown in Figure 2A, peptide AR71 
(sequence: Ac-FHWRYPLPLPGQ-NH2) was found to be particularly potent in dissociating 
MIA dimers which led to a decrease in FP signal due to increased rotational diffusion of the 
dissociated monomeric MIA-Ru(bpy)3. This effect of AR71 was confirmed by Western Blot 
analysis (Figure 2B). Preincubation of MIA with 1 µM peptide AR71 leads to a strong 
reduction of the dimer bands compared to the control lane or other MIA-binding peptides 
used (AR68, AR69).  
To prove that AR71 functionally inhibits MIA, Boyden chamber invasion assays were 
performed (Figure 2C). In these in vitro experiments, MIA interferes with the attachment of 
cells to matrigel, as reflected by a decrease in cell invasion. After external treatment with 
MIA, invasion of Mel Im cells is significantly reduced about 40% to 50% compared to 
untreated control cells. Pre-incubation of MIA with the inhibitory peptide AR71 results in a 
complete neutralization of the effect caused by MIA, as reflected in the number of invaded 
cells. Treatment of cells with peptide AR71 alone does not influence the migratory behaviour 
of melanoma cells.  
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Figure 2. Peptide AR71 prevents MIA dimerization. (A) Heterogeneous transition-metal 
based fluorescence polarization (HTFP) assay for probing AR71 for its ability to directly 
interfere with MIA-MIA interaction. In the control lanes the FP signal of MIA-Ru(bpy)3 was 
measured in a well coated with MIA-biotin compared to an uncoated well. The significant 
increase in FP in the well coated with MIA-biotin indicates binding of MIA-Ru(bpy)3 to the 
immobilized MIA-biotin. The binding of MIA-inhibitory compound AR71 promotes 
dissociation of MIA dimers and displaces the surface-bound MIA-Ru(bpy)3, as reflected by 
the decrease in fluorescence polarization. Peptides AR68 and AR69, also derived from a 
phage display, do not interfere with MIA-MIA interaction. (B) Western Blot analysis of MIA 
incubated with 1 µM AR71 demonstrates peptide-induced dissociation of the dimer, as 
deduced by a strong reduction of the dimer band compared to the control lane. MIA-binding 
peptides AR68 and AR69 do not lead to reduced dimer formation. (C) Boyden chamber 
invasion assays using the human melanoma cell line Mel Im indicate that AR71 almost 
completely inhibits MIA activity. Interference of MIA with cell attachment to matrigel results 
in a decrease in cell invasion; after external treatment with MIA invasion of Mel Im cells is 
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significantly reduced about 40% to 50% compared to untreated control cells. Pre-incubation 
of MIA with the respective inhibitory peptide results in a complete neutralization of the MIA 
effect. The two control lanes confirm that AR71 alone does not influence the migratory 
behaviour since exposure of cells to the peptide in absence of MIA does not alter the quantity 
of migrated cells. 
 
 
MIA interacts with AR71 
After demonstrating the potential of AR71 to inhibit MIA function in in vitro models, we 
could show by multidimensional NMR spectroscopy that MIA binds to this peptide ligand. In 
addition, the potential binding site of AR71 was identified using 15N labeled MIA and 
unlabeled peptide. By using increasing amounts of AR71 peptide, the induced chemical shift 
changes of the MIA 1HN and 15NH resonances were classified according to the degree of the 
combined chemical shift perturbations. Further analysis of the solvent accessibility (with a 
threshold of 20 %) and cluster analysis of the residues effected by peptide binding reveals that 
the binding interface potentially comprises residues C17, S18, Y47, G66, D67, L76, W102, 
D103 and C106 of MIA (Figure 3A) It can therefore be assumed that the peptide 
predominantly binds to the binding site depicted on the left side of Figure 3A, whereas the 
opposite side of the molecule most probably does not participate in binding.  
 
After stably transfecting B16 mouse melanoma cells with a secretion-signal containing AR71-
HisTag construct (Sig-AR71-HisTag), we first analysed expression and localization of 
endogenous AR71-HisTag peptide. Co-staining of MIA protein and AR71-HisTag revealed a 
colocalization in close proximity to the nucleus. Immunofluorescence studies show the 
localization of MIA (green, Figure 3Ba) and AR71-HisTag (for demonstrating colocalization 
with MIA, the red TRITC emission has been changed to yellow in this false-color illustration, 
Figure 3Bb). The colocalization, depicted in red, is indicated by white arrows in Figure 3Bc. 
The excess of MIA not colocalized with AR71 is due to internalization of exogenous MIA 
protein by the melanoma cells.62 Figure 3Bd shows the corresponding mock control.  
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Figure 3. Chemical shift differences of MIA upon titration with the dodecapeptide AR71. (A) 
Most significant chemical shift differences projected onto the van der Waals surface of MIA 
upon titration with the peptide AR71 are shown in red. The binding site is located in the 
dimerization domain next to the distal loop (compare Figure 1D). This figure was generated 
using PyMol (Delano, W. L., The PyMol Molecular Graphics System (2002) Delano 
Scientific, Palo Alto, CA, USA). (B) Immunofluorescence studies of murine B16 melanoma 
cells stably transfected with a (Sig)-AR71-HisTag construct. While a) shows MIA (FITC) and 
b) displays AR71-HisTag (TRITC with color changed from red to yellow for better 
visualization of colocalization), colocalization shown in red is indicated by white arrows in c). 
d) Corresponding mock control without AR71-HisTag.  
 
 
Effect of MIA inhibitory peptide AR71 on formation of metastases in vivo 
MIA expression levels of malignant melanoma cells strictly correlate with a highly invasive 
phenotype in vitro and in vivo.57, 80, 81 Further, in vivo studies have demonstrated the strong 
contribution of MIA for melanoma cell invasion and migration.71, 72 
In order to assess the ability of peptide AR71 to inhibit the formation of metastases by 
generating inactive MIA monomers in vivo, a previously developed metastasis assay was 
employed.82 In this assay, melanoma cells metastasize from the primary tumor in the spleen 
via the portal vein into the liver. Nine days after injection of the cells into the spleen, the mice 
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were sacrificed, the livers were resected and tissue sections were prepared. Here, we used the 
stably transfected murine B16 melanoma cells with a Sig-AR71-HisTag containing construct. 
In vitro analysis by Boyden chamber assay confirmed that migration is drastically reduced in 
Sig-AR71-HisTag expressing cell clones compared to mock control cells (Figure 4A). The 
interference of AR71-HisTag with MIA-MIA interaction was also confirmed in the HTFP 
assay using wells coated with MIA-biotin (data not shown). Subsequently, a Sig-AR71-
HisTag clone as well as a corresponding mock control was injected into the spleen of C57Bl6 
mice, respectively. Histological analysis of haematoxylin and eosin stained liver sections 
revealed that mice being injected with Sig-AR71-HisTag clones comprised significantly 
fewer metastases than the mock control (Figure 4B). Four representative histological liver 
sections (hematoxylin and eosin stained) of mice injected with the B16 mock control or mice 
injected with the Sig-AR71-HisTag expressing cell clone, respectively, are shown in Figure 
4C. Black arrows indicate the small metastases in the mock control which are exceedingly 
reduced in the liver of mice injected with the Sig-AR71-HisTag expressing cell clone. No 
adverse effects of AR71 on other organs and tissues were observed. 
These results prompted us to investigate whether AR71 peptide could also reduce the 
formation of metastases when given as an i.v. administration treatment. Therefore, wild type 
murine B16 melanoma cells were injected into the spleen of C57Bl6 mice with the mice being 
subsequently treated with i.v. injections of AR71 (50 µg every 24 h). After nine days, the 
mice were sacrificed, the livers were resected and again tissue sections were prepared. 
Histological analyses revealed a significant reduction of the average number of metastases in 
the liver of mice treated with AR71 compared to the liver of untreated control mice, as shown 
in figure Figure 4D. Four representative histological liver sections (hematoxylin and eosin 
stained) of untreated and treated mice, respectively, are shown in Figure 4E. Again no adverse 
effects on other organs and tissues were observed.  
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Figure 4. Effect of MIA inhibitory peptide AR71 on formation of metastases in vivo. (A) 
Murine B16 melanoma cells stably transfected with a (secretion-signal)-AR71-HisTag 
containing construct were analyzed for their migratory activity in a Boyden chamber assay. 
Compared to the mock control, migration is drastically reduced in the two Sig-AR71-HisTag 
expressing cell clones clone K2 and clone K4. (B) Sig-AR71-HisTag clone K4 as well as a 
corresponding mock control were injected into the spleen of Bl/6N mice, respectively. 
Histological analysis of haematoxylin and eosin stained liver sections revealed that mice 
being injected with Sig-AR71-HisTag clones comprised significantly fewer metastases than 
the mock control. (C) Representative histological liver sections (hematoxylin and eosin 
stained), two of mice injected with the B16 mock control (a and a’) and two of mice injected 
with the Sig-AR71-HisTag expressing cell clone K4 (b and b’). Black arrows indicate small 
metastases. (D) Wild type murine B16 melanoma cells were injected into the spleen of Bl/6N 
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mice with the mice being subsequently treated with i.v. injections of AR71 (50 µg every 24 
h). Histological analyses revealed a significant reduction of the average number of metastases 
in the liver of mice treated with AR71 compared to the liver of untreated control mice. (E) 
Representative histological liver sections (hematoxylin and eosin stained), two of untreated (a 
and a’) and two of treated mice (b and b’). 
 
2.2.3 Discussion of the inhibition studies 
Primary melanomas often reach a high proliferation rate and acquire competence for 
metastasis in early stages of the disease. As already presented in previous studies, MIA plays 
a fundamental role in this process.60, 71 However, hitherto the molecular mechanism by which 
MIA enables tumor cell release from the primary tumor and promotes formation of metastases 
elsewhere in the body was poorly understood. 
Here, we newly describe that MIA is active as a dimer. MIA dimerization is supported by in 
silico studies as well as Western blot analysis, mutagenesis studies and HTFP assay 
measurements.79 We identified the probable dimerization domains as being located in the n-
Src loop and in the cleft next to the distal loop. Additionally, this tendency of MIA to form 
homomeric linkages was also indicated by previous NMR spectroscopy experiments revealing 
a transversal relaxation time (T2) shorter than expected for an 11 kDa protein.76, 83  
However, until now, dimerization of MIA has not been correlated with functional activity. 
Our studies revealed that MIA is functionally inactive as a monomeric species and only 
wt MIA and MIA mutants still forming dimers were found to be functionally active in 
Boyden chamber invasion assays. The mutants D29G/Y69H, V46F/S81P, T89P and K91N 
are still able to dimerize. Replacement of these amino acids outside the dimerization domains 
in the n-Src loop and next to the distal loop does not hinder dimerization and consequently 
does not influence functional activity. In contrast, the mutation G61R is located at the 
dimerization interface next to the distal loop of MIA. In this mutant, glycine, an uncharged 
amino acid residue with minimum sterical demand is replaced by arginine, a positively 
charged and very large residue. As expected, this exchange strongly impacts formation of 
MIA dimers due to sterical demand and charge repulsion between the two respective MIA-
MIA binding sites. The fact that monomeric MIA is functionally completely inactive suggests 
that the active site for integrin and ECM binding could potentially be generated by self 
assembly of two identical MIA subunits.  
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The concept of proteins that require dimerization in order to reach functional activity has been 
described for example for lipoprotein lipase which is converted into inactive monomers by 
angiopoietin-like protein 4. Concomitant with dissociation of functionally active dimers into 
monomers, an irreversible loss of catalytic activity was found.84 Furthermore, this functional 
coupling between oligomerization and activity of proteins has also been reported for 
herpesvirus protease, which is also inactivated after dimer disruption.85, 86  
The feasibility of inhibiting protein activity via preventing dimerization was discussed in a 
study by Wlodawer et al. describing a similar mechanism for inhibiting HIV-1 protease, a 
homodimeric protein requiring dimerization for activation.87 The inhibition is achieved by 
targeting the dimerization interface using peptides promoting dissociation.88 The design of 
small molecules intended to disrupt the dimer and /or bind to an inactive protein monomer, 
therefore, offers an alternative to the strategy of targeting of the active site. 
In our search for MIA inhibitory compounds, we employed the HTFP assay as a rapid 
screening platform to identify peptides that prevent the assembly of inactive monomers to 
functionally active MIA dimers. The dodecapeptide AR71 was found to exhibit significant 
MIA inhibitory effect in in vitro experiments. As reflected by the HTFP assay and Western 
Blot analysis, inhibitory peptide AR71 promotes dissociation of MIA aggregates, while our 
NMR investigations revealed it to directly bind to the dimerization domain next to the distal 
loop.  
Having demonstrated the inhibitory effect of AR71 in the in vitro models, we employed an 
established in vivo metastasis assay to evaluate the capability of peptide AR71 to prevent the 
formation of metastasis of malignant melanoma by inhibiting MIA.82 In our first model, Sig-
AR71-HisTag expressing B16 cell clones and the respective mock control cells were analyzed 
for their metastatic potential. With the addition of an N-terminal secretion sequence ensuring 
peptide processing into the endoplasmic reticulum, we expected subsequent binding and thus 
inactivation of MIA by preventing formation of functionally active protein dimers directly at 
the location of protein biosynthesis. In immunofluorescence studies we could observe this 
colocalization of MIA and AR71-HisTag in the cells. In an in vivo mouse model, the 
expression of AR71 by the stably transfected B16 cells led to a dramatic reduction in the 
formation of metastases compared to mock control, again reflecting the need for MIA to form 
dimers to reach functional activity. 
Even though peptides are generally quickly degraded in vivo by proteases and renally cleared, 
we also observed a significant reduction in the formation of metastases in an in vivo injection 
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model of AR71. Again, the particularly strong reduction in the number of metastases proves 
the potency of AR71 to suppress the metastatic spread of melanoma cells in vivo.  
To conclude, we have contributed to the understanding of the molecular function of MIA by 
in vitro studies which included multidimensional NMR spectroscopy. These investigations 
revealed that MIA is functionally active as a dimer. By specifically screening MIA-binding 
peptide ligands for their ability to prevent MIA dimerization, we identified dodecapeptide 
AR71 and demonstrate the potency of this peptide to significantly reduce the formation of 
metastases of murine B16 malignant melanoma cells in vivo. This study details the 
mechanism by which peptide AR71 inhibits MIA mediated metastatic spread of tumor cells 
and provides a novel leading structure for the design of potent therapeutics for the treatment 
of malignant melanoma. To overcome the drug resistance observed with current treatments, 
this new strategy of dimerization inhibitors may be useful for prevention or at least reduction 
of metastastatic spread in early stages of the disease. Specifically inhibiting the formation of 
metastases should provide a very effective therapy since malignant melanoma is not fatal 
because of the primary tumor but because of organ failure due to formation of metastases. In 
addition, most conventional treatments still affect cancer cells as well as other fast-dividing 
cell types, resulting in the desire for a more targeted therapy. By targeting MIA, which is only 
expressed in malignant melanoma and in early-phase differentiating chondrocytes, the adverse 
reactions of treatment with MIA inhibitory compounds should be minimal. Side effects on 
cartilage are not expected since MIA-deficient mice show no phenotype changes, as 
previously demonstrated.89  
We feel that this study provides an excellent starting point for the development of a new 
strategy in malignant melanoma therapy. Targeting MIA leads to strongly reduced tumor cell 
invasion and formation of metastases and thus provides a new concept of therapeutic 
intervention. 
 
2.2.4 Materials and Methods 
 
Cell lines and cell culture conditions 
The melanoma cell line Mel Im, established from a human metastatic bioptic sample 
(generous gift from Dr. Johnson, University of Munich, Germany) was used in all 
experiments. Additionally, main experiments were also conducted using the human cell line 
Mel Ju and the murine cell line B16, which were derived from metastases of malignant 
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melanoma. All cells were maintained in DMEM (PAA Laboratories GmbH, Cölbe, Germany) 
supplemented with penicillin (400 U/mL), streptomycin (50 µg/mL), l-glutamine (300 
µg/mL) and 10% fetal calf serum (Pan Biotech GmbH, Aidenbach, Germany) and split in a 
1:6 ratio every 3 days. 
 
Protein analysis in vitro (Western blotting) 
Protein samples were denaturated at 70°C for 10 min after addition of reducing and 
denaturing Roti-Load buffer (Roth, Karlsruhe, Germany) and subsequently separated on 
sodium dodecyl sulfate 12.75% polyacrylamid gels (SDS-PAGE) (Invitrogen, Groningen, The 
Netherlands). In the multimerization studies, MIA protein (1 µg) was incubated with AR71 
(2.5 µg) overnight at RT before being treated as described above. After transferring the 
proteins onto a polyvinylidene fluoride (PVDF) membrane (BioRad, Richmond, VA, USA), 
the membrane was blocked using 3% BSA/PBS for 1 h at RT and incubated with a 1:150 
dilution of primary polyclonal rabbit anti MIA antibody (Biogenes, Berlin, Germany) in 3% 
BSA/PBS overnight at 4°C. After washing in PBS the membrane was incubated with a 1:2000 
dilution of an alkaline-phosphatase coupled secondary antibody (Chemikon, Hofheim, 
Germany) for 2 h at RT. Finally, after washing steps, immunoreactions were visualized by 
nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) (Invitrogen, 
Karlsruhe, Germany) staining.  
 
Boyden Chamber Invasion Assay 
Invasion assays were performed in Boyden Chambers containing polycarbonate filters with 8-
µm pore size (Neuro Probe, Gaithersburg, MD, USA) essentially as described previously.69 
Filters were coated with matrigel, a commercially available reconstituted basement membrane 
(diluted 1:3 in H2O; BD Bioscience, Bradford, MA, USA). The lower compartment was filled 
with fibroblast-conditioned medium used as a chemo attractant. Mel Im melanoma cells were 
harvested by trypsinization for 2 min at RT, resuspended in DMEM without FCS at a density 
2.5 x 104 cells/mL, and placed in the upper compartment of the chamber. Except for the 
control experiment with untreated cells and experiments where cells were only treated with 
the respective peptide, MIA was added to the cell suspension at a final concentration of 
200 ng/mL. Peptide AR71 (sequence: Ac-FHWRYPLPLPGQ-NH2) was used at a final 
concentration of 1 µM. MIA expressing murine B16 melanoma cells stably co-transfected 
with Sig-AR71-HisTag containing pCMX-PL1 vector90 and an antibiotic resistance 
comprising plasmid (pCDNA3), and the respective mock control were also investigated for 
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their ability to migrate. Therefore, cells were harvested by trypsinization for 2 min at RT, 
resuspended in DMEM without FCS at a density 2.5 x 104 cells/mL, and placed in the upper 
compartment of the chamber. After incubation at 37°C for 4 h filters were removed. Cells 
adhering to the lower surface of the filter were fixed, stained, and counted. Experiments were 
carried out in triplicates and repeated at least three times. 
 
Coating of well plates with MIA-biotin 
Black, streptavidin coated 96 well plates (from Greiner Bio-one, Frickenhausen, Germany) 
were coated with MIA-biotin as described previously.59, 79 An uncoated control lane was 
sealed with adhesive film to prevent contamination. The MIA-biotin coated plate was used for 
measurements immediately. 
 
Polarization assay setup 
All measurements were performed at RT on a Polarstar Optima microplate reader (BMG 
Labtech, Offenburg, Germany). A 390-10 nm bandpass filter was used for excitation while a 
520 nm longpass filter was used for the emission light. Even though the extinction coefficient 
is higher at longer wavelengths, we chose a shorter excitation wavelength as this led to higher 
polarization values. MIA-Ru(bpy)3 was prepared and tested for functional activity as 
described previously.79 A MIA-Ru(bpy)3 concentration of 55 fM was used in all experiments. 
A solution volume of 250 µL per well was found to give a low standard deviation with high 
signal intensity. All measurements were performed in DPBS without calcium or magnesium 
(PAN Biotech GmbH, Aidenbach, Germany). Addition of components to the wells was done 
in the following order: inhibitory peptide, buffer, MIA-Ru(bpy)3. Owing to different reaction 
kinetics, measurements were performed every 5 min over a 30 min period. Polarization values 
are reported relative (P/P0) to the value of free MIA-Ru(bpy)3 in solution in a well not treated 
with MIA-biotin. All reported values are an average of three independent measurements.  
 
Cloning Strategy  
Signal-AR71-HisTag pCMX-PL1-plasmid construction: The Signal-AR71-HisTag pCMX-
PL1 expression plasmid was created by PCR amplification of the human hydrophobic signal-
peptide sequence, responsible for transport into the endoplasmic reticulum, from a Signal-
MIA containing expression plasmid using the MJ Research PTC-200 Peltier Thermo Cycler 
(BioRad, Munich, Germany). The HisTag sequence was inserted at the C-terminal end of the 
AR71 peptide using the primers 5’- GAC GAA TTC ATG GCC CGG TCC CTG GTG - 3’ 
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and 5’- GAC AAG CTT TCA GTG ATG GTG ATG GTG ATG CTG GCC GGG CAA GGG 
CAA GGG GTA TCT CCA GTG GAA CCT GAC ACC AGG TCC GGA GAA -3’. After 
amplification of the Signal-AR71-HisTag fragment, the PCR product was digested with 
EcoRI and HindIII (NEB, Frankfurt, Germany). The insert was purified by gel extraction 
(Qiagen, Hilden, Germany) and cloned into the EcoRI and HindIII sites of the eukaryotic 
expression vector pCMX-PL1 which was previously purified and prepared for ligation using 
T4-Ligase (NEB, Frankfurt, Germany).90 After transformation in DH10ß cells (NEB, 
Frankfurt, Germany) according to the manufacturer´ s instructions, the plasmid was isolated 
using the MIDI Kit (Qiagen, Hilden, Germany) and quantified by a gene quant II RNA/DNA 
Calculator (Pharmacia Biotech, Nümbrecht, Germany). The sequence of the PCR-generated 
clone was confirmed by DNA sequencing.  
 
Stable transfection of murine B16 melanoma cells 
For transfection, 1.5 x 105 cells/mL were seeded in 6-well plates (Corning Omnilab, Munich, 
Germany) and cultured in 2 mL of Dulbecco’s modified Eagle’s medium (PAA, Cölbe, 
Germany) with 10% fetal calf serum (Pan, Aidenbach, Germany). Cells were transfected with 
0.8 µg of the respective control or His-tagged AR71 containing pCMX-PL1 vector and 0.2 µg 
pcDNA3 providing geneticin (Invitrogen, Karlsruhe, Germany) resistance using the 
LipofectaminPlus (Invitrogen, Karlsruhe, Germany) method according to the manufacturer’s 
instructions. After selection of cells comprising antibiotic resistance we confirmed expression 
and localization of AR71 peptide on mRNA and protein level by PCR and 
immunofluorescence, respectively. 
 
Recombinant expression of MIA and mutant forms 
In vitro protein expression reactions of recombinant human MIA and its mutants were 
performed with the Rapid Translation System RTS 500 E. coli HY Disulfite Kit (Roche, 
Mannheim, Germany) according to the manufacturer’ s instructions. All reactions were 
carried out over night at 30°C or 25°C with efficient stirring in the RTS 500 instrument. MIA 
mutants were checked for correct folding and function as previously described.69  
 
NMR Spectroscopy  
All spectra were recorded at 300 K and pH 7 on a Bruker DRX600 spectrometer equipped 
with a pulsed field gradient triple resonance probe. Water suppression in experiments 
recorded on samples in H2O was achieved by incorporation of a Watergate sequence into the 
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various pulse sequences.91, 92, 93 2D 1H-15N HSQC spectra with reduced signal loss due to 
fast  exchanging protons were recorded using procedures described previously.94 All spectra 
were processed with NMRPipe and analyzed with NMRView.95, 96 Data handling was 
performed with NMRView. Structure visualisation and superimpositions were done with 
PyMol (Delano, W. L., The PyMol Molecular Graphics System (2002) Delano Scientific, 
Palo Alto, CA, USA). 
 
Dimer model 
The PreBI modelling software (http://pre-s.protein.osaka-u.ac.jp/prebi/) was used together 
with the published X-ray structure of MIA (PDBid: 1I1J) for the prediction of the putative 
dimer interface. Employing the monomeric NMR structure of MIA (PDBid: 1HJD) together 
with the interface information obtained in the previous step a three-dimensional model of the 
dimeric complex was calculated. Computations were performed using the data driven protein-
protein docking program HADDOCK.78 
 
Protein binding studies 
The NMR titration of MIA with AR71 consisted of monitoring changes in chemical shifts and 
line widths of the backbone amide resonances of uniformly 15N-enriched MIA samples as a 
function of ligand concentration.97, 98, 99, 100  
 
In vivo metastasis assay  
To determine the effect of peptide AR71 on the metastatic potential of murine B16 melanoma 
cells in vivo, a previously developed mouse metastases model was used.82 1 x 105 cells of the 
AR71-HisTag expressing B16 cell clone AR71-His K4 as well as the corresponding mock 
control cells were injected into the spleen of mice (n = 8 for mock control cells as well as for 
AR71-HisTag K4 cells, respectively). After nine days, mice were sacrificed, the livers were 
resected and the number and size of visible black tumor nodules on the surface of the livers 
were noticed. Tissues were fixed in formalin and afterwards paraffin embedded sections were 
hematoxylin and eosin stained for histological analysis. 
Additionally, 1 x 105 wt mouse melanoma B16 cells suspended in a solution containing AR71 
(1 mg/mL) and 0.9% NaCl, or NaCl alone for the control mice, respectively, were injected 
into the spleen of each animal (n = 8 for treated mice, as well as for control without AR71). 
Peptide AR71 was injected i.v. (50 µg every 24 h). After nine days, the mice were sacrificed 
and the livers were excised. Following formalin fixation, tissues were embedded in paraffin. 
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Afterwards, sections were prepared and stained using hematoxylin and eosin before being 
subjected to histological analysis. 
 
Immunofluorescence assays 
5 x 105 murine B16 melanoma cells were grown in a 4-well chamber slide (Falcon, BD 
Bioscience, Heidelberg, Germany). After stable transfection with a Sig-AR71-HisTag 
containing expression plasmid and the respective pCMX-PL1 mock control, cells were 
incubated for 48 h at 37°C and 8% CO2. Afterwards, cells were washed and fixed using 4% 
paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) for 15 min. After 
permeabilization of cells, blocking of non-specific binding sites with blocking solution (1% 
BSA/PBS) for 1 h at 4°C was performed. Cells were incubated with primary antibodies rabbit 
anti-MIA (Biogenes, Berlin, Germany) and mouse anti-HisTag (BD Bioscience, Pharmingen, 
Germany) at a concentration of 1 µg/mL at 4°C for 2 h. After rinsing with PBS five times, 
cells were first covered with a 1:200 dilution of the secondary antibody TRITC anti-mouse 
(TRITC-conjugated donkey anti-mouse antibody, Jackson Immuno Research Laboratories, 
West Grove, PA, USA) and FITC anti-rabbit (FITC-conjugated polyclonal swine anti rabbit 
immunoglobulin, DakoCytomation, Glostrup, Denmark) in PBS at 4°C for 1 h, respectively. 
Following incubation with primary antibodies, cells were washed with PBS and coverslips 
were mounted on slides using Hard Set Mounting Medium with DAPI (Vectashield, H-1500, 
Linearis, Wertheim Germany) and imaged using an Axio Imager Zeiss Z1 fluorescence 
microscope (Axiovision Rel. 4.6.3) equipped with an Axio Cam MR camera. Images were 
taken using 63x oil immersion lenses.  
 
Statistical analysis 
In the bar graphs, results are expressed as mean ± S.D. (range) or percent. Comparison 
between groups was made using the Student's unpaired t-test. A p-value <0.05 was considered 
as statistically significant (ns: not significant, *: p<0.05, **: p<0.01, ***: p<0.001). All 
calculations were made using the GraphPad Prism Software (GraphPad Software, Inc., San 
Diego, USA). 
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3. Summary in English and in German 
 
English 
The first part of this thesis describes the use of artificial metal chelate receptors for the 
recognition of phosphorylated peptides and proteins. Ditopic receptors were used for the 
differentiation of phosphorylated peptides in solution. After observing binding of a bis-Zn(II)-
cyclen triazine to phosphorylated amino acids in a peptide in this project, new receptors were 
synthesized with the binding moiety coupled to a fluorophore. These compounds were then 
established for the detection of protein phosphorylation on SDS-PAGE. 
The second part of this thesis describes a novel fluorescence polarization assay for 
investigating interactions of proteins with other proteins or small molecules. This assay 
significantly increases the molecular weight of the interaction partner which can be observed 
with traditional polarization assays using organic fluorophores by using a luminescent 
transition metal label and a functionalized wellplate as an interaction partner. In addition, a 
peptide deduced from this assay as inhibiting MIA (melanoma inhibitory activity) protein was 
found to inhibit the formation of metastases of malignant melanoma in vivo by belonging to a 
new class of cancer treatment agents, the anti metastatic agents.  
 
German 
Der erste Teil dieser Arbeit beschreibt die Verwendung von bis-Zn(II)-Cyclen Triazin 
Komplexen zur molekularen Erkennung von phosphorylierten Peptiden und Proteinen. 
Rezeptoren mit zwei Bindungsstellen wurden verwendet um phosphorylierte Peptide in 
Lösung zu unterscheiden. Ausgehend von diesen Ergebnissen wurden Fluoreszenz-markierte 
Metall Chelate zur Detektion von phosphorylierten Proteinen in der SDS-PAGE etabliert.  
Der zweite Teil dieser Arbeit beschreibt einen neuartigen Fluoreszenzpolarisations Assay für 
die Beobachtung von Protein Wechselwirkungen. Im Gegensatz zu herkömmlichen 
Polarisations Assays mit organischen Fluorophoren wurde hier durch die Verwendung einer 
lumineszenten Übergangsmetall Chelat Markierung und einer funktionalisierten Wellplate das 
Spektrum der Molekularmasse des Wechselwirkungspartners erheblich erweitert. Ein mit 
diesem Assay gefundener Inhibitor für das MIA (melanoma inhibitory activity) Protein 
konnte zudem als erster Inhibitor für die Metastasierung des malignen Melanoms in vivo 
demonstriert werden und stellt damit eine gezielt anti-metastatische Tumorbehandlung dar.  
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4. Abbreviations 
 
Ac    acetyl 
AcOH    acetic acid 
BCIP    5-bromo-4-chloro-3-indolyl phosphate 
Boc    tert-butyloxycarbonyl 
BSA    bovine serum albumin 
DCM    dichloromethane 
CBB    coomassie brilliant blue 
Chk2    checkpoint kinase 2 
DIC    N,N´-diisopropylcarbodiimide 
DIPEA    diisopropylethylamine 
DLS    dynamic light scattering 
DMEM    Dulbecco’s modified eagle medium 
DMF    N,N-dimethylformamide 
DMSO    dimethyl sulfoxide 
DPBS    Dulbecco’s phosphate buffered saline 
ECM    extracellular matrix 
EDTA    ethylenediamine tetraacetic acid 
EGTA    ethyleneglycol tetraacetic acid 
ELISA    enzyme-linked immunosorbent assay 
ESI    electrospray ionization 
FCS    fetal calf serum 
FHA    forkhead associated domain 
Flu    fluorescein 
Fmoc    fluorenyl-9-methoxycarbonyl 
FP    fluorescence polarization 
FRET    fluorescence resonance energy transfer 
HBTU    O-(1-benzotriazolyl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 
HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HOBt     hydroxybenzotriazole 
HTFP    heterogeneous transition metal-based fluorescence polarization 
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ITC    isothermal titration calorimetry 
kDa    kilo Dalton 
MeOH    methanol 
MIA    melanoma inhibitory activity 
MS    mass spectrometry 
MW    molecular weight 
NBT    nitro blue tetrazolium 
NMP    N-methyl-2-pyrrolidone 
NMR    nuclear magnetic resonance 
NTA    nitrilo triacetic acid 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
Pin1    peptidyl-prolyl cis/trans isomerase (never in mitosis gene a)-interacting 1 
PPase    phosphatase 
PVDF    polyvinylidene fluoride 
RT    room temperature 
Ru(bpy)3    tris(2,2'-bipyridine) ruthenium (II) 
SDS-PAGE    sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SH2    sarcoma homology 2 
SPPS    solid-phase peptide synthesis 
STAT    signal transducer and activator of transcription 
TBTU    O-(benzotriazol-1-yl)- N,N,N',N'-tetramethyluronium tetrafluoroborate 
TFA    trifluoroacetic acid  
TIS    triisopropylsilane 
TRIS    tris(hydroxymethyl) aminomethane 
Trt    trityl 
UV    ultraviolet 
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